- Home
- EVG vs MCRB Comparison
EVG vs MCRB Comparison
Compare EVG & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVG
- MCRB
- Stock Information
- Founded
- EVG 2005
- MCRB 2010
- Country
- EVG United States
- MCRB United States
- Employees
- EVG N/A
- MCRB N/A
- Industry
- EVG Investment Managers
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- EVG Finance
- MCRB Health Care
- Exchange
- EVG Nasdaq
- MCRB Nasdaq
- Market Cap
- EVG 149.7M
- MCRB 144.6M
- IPO Year
- EVG N/A
- MCRB 2015
- Fundamental
- Price
- EVG $11.00
- MCRB $18.75
- Analyst Decision
- EVG
- MCRB Hold
- Analyst Count
- EVG 0
- MCRB 4
- Target Price
- EVG N/A
- MCRB $14.33
- AVG Volume (30 Days)
- EVG 49.4K
- MCRB 123.5K
- Earning Date
- EVG 01-01-0001
- MCRB 11-12-2025
- Dividend Yield
- EVG 8.68%
- MCRB N/A
- EPS Growth
- EVG N/A
- MCRB N/A
- EPS
- EVG N/A
- MCRB 10.22
- Revenue
- EVG N/A
- MCRB N/A
- Revenue This Year
- EVG N/A
- MCRB N/A
- Revenue Next Year
- EVG N/A
- MCRB N/A
- P/E Ratio
- EVG N/A
- MCRB $1.93
- Revenue Growth
- EVG N/A
- MCRB N/A
- 52 Week Low
- EVG $9.13
- MCRB $6.53
- 52 Week High
- EVG $10.86
- MCRB $24.67
- Technical
- Relative Strength Index (RSI)
- EVG 47.69
- MCRB 48.12
- Support Level
- EVG $10.95
- MCRB $18.54
- Resistance Level
- EVG $11.24
- MCRB $21.50
- Average True Range (ATR)
- EVG 0.13
- MCRB 1.28
- MACD
- EVG -0.01
- MCRB -0.21
- Stochastic Oscillator
- EVG 46.27
- MCRB 6.12
About EVG Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest
Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.